Total Payments
$168,797
2024 Payments
$26,735
Companies
30
Transactions
376
Medicare Patients
2,367
Medicare Billing
$243,859
Payment Breakdown by Category
Other$153,025 (90.7%)
Food & Beverage$8,318 (4.9%)
Travel$7,445 (4.4%)
Education$9.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $153,025 | 69 | 90.7% |
| Food and Beverage | $8,318 | 238 | 4.9% |
| Travel and Lodging | $7,445 | 68 | 4.4% |
| Education | $9.00 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $164,713 | 208 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,009 | 40 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $543.57 | 18 | $0 (2024) |
| Insmed, Inc. | $348.84 | 13 | $0 (2024) |
| Electromed, Inc. | $247.37 | 17 | $0 (2024) |
| Grifols USA, LLC | $235.36 | 13 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $216.17 | 9 | $0 (2024) |
| Mylan Specialty L.P. | $160.84 | 8 | $0 (2024) |
| Amgen Inc. | $152.82 | 3 | $0 (2024) |
| Genentech, Inc. | $128.57 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $26,735 | 71 | AstraZeneca Pharmaceuticals LP ($25,877) |
| 2023 | $47,876 | 86 | AstraZeneca Pharmaceuticals LP ($47,039) |
| 2022 | $24,279 | 33 | AstraZeneca Pharmaceuticals LP ($24,180) |
| 2021 | $64,056 | 139 | AstraZeneca Pharmaceuticals LP ($62,606) |
| 2020 | $5,850 | 47 | AstraZeneca Pharmaceuticals LP ($5,011) |
All Payment Transactions
376 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Respiratory | ||||||
| 11/06/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $33.41 | General |
| Category: Cardiology | ||||||
| 11/05/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $2.94 | General |
| Category: Inflammation | ||||||
| 10/30/2024 | PFIZER INC. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug), PANZYGA, CUTAQUIG | Food and Beverage | In-kind items and services | $21.11 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Respiratory | ||||||
| 10/21/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $20.10 | General |
| Category: Respiratory | ||||||
| 10/21/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $14.98 | General |
| Category: Respiratory | ||||||
| 10/17/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: Respiratory | ||||||
| 10/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $26.29 | General |
| Category: RESPIRATORY | ||||||
| 10/09/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $20.59 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/03/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $76.80 | General |
| Category: RESPIRATORY | ||||||
| 09/30/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,850.00 | General |
| Category: Respiratory | ||||||
| 09/26/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $26.94 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $106.71 | General |
| Category: Respiratory | ||||||
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $16.75 | General |
| Category: Respiratory | ||||||
| 09/23/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $16.12 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 09/13/2024 | Pulmonx Corporation | CHARTIS CATHETER (Device), PULMONX CHARTIS TABLET CONSOLE, ZEPHYR ENDOBRONCHIAL VALVE | Food and Beverage | In-kind items and services | $67.52 | General |
| Category: PULMONOLOGY | ||||||
| 09/11/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $21.28 | General |
| Category: Respiratory | ||||||
| 09/09/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $15.68 | General |
| Category: RESPIRATORY | ||||||
| 08/29/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,750.00 | General |
| Category: Respiratory | ||||||
| 08/29/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $31.47 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/21/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $17.98 | General |
| Category: Respiratory | ||||||
| 08/14/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 08/08/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| Category: Respiratory | ||||||
| 07/31/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $25.87 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 622 | 770 | $262,746 | $44,297 |
| 2022 | 5 | 125 | 139 | $46,181 | $12,310 |
| 2021 | 15 | 891 | 1,515 | $195,385 | $107,927 |
| 2020 | 16 | 729 | 1,192 | $142,710 | $79,325 |
Total Patients
2,367
Total Services
3,616
Medicare Billing
$243,859
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 66 | 105 | $50,038 | $9,755 | 19.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 85 | 85 | $61,300 | $9,246 | 15.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 49 | 95 | $30,375 | $5,525 | 18.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 26 | 58 | $26,790 | $5,246 | 19.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 52 | 53 | $32,338 | $5,185 | 16.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 50 | 61 | $19,323 | $3,849 | 19.9% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 14 | 15 | $10,645 | $1,347 | 12.7% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 11 | 11 | $8,425 | $885.50 | 10.5% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2023 | 23 | 23 | $4,077 | $767.74 | 18.8% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 25 | 26 | $6,382 | $584.43 | 9.2% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 67 | 69 | $3,945 | $578.77 | 14.7% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 69 | 73 | $4,464 | $516.60 | 11.6% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 67 | 69 | $2,952 | $433.35 | 14.7% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2023 | 18 | 27 | $1,692 | $378.00 | 22.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 52 | 52 | $21,294 | $5,653 | 26.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 33 | 35 | $7,329 | $3,137 | 42.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 27 | $8,451 | $1,466 | 17.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 12 | 12 | $7,152 | $1,235 | 17.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 13 | $1,955 | $819.57 | 41.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 113 | 418 | $62,700 | $32,945 | 52.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 137 | 253 | $31,625 | $22,856 | 72.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 74 | 76 | $17,100 | $11,513 | 67.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 67 | 202 | $20,200 | $11,133 | 55.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 105 | 144 | $11,520 | $8,671 | 75.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 66 | 66 | $11,880 | $8,063 | 67.9% |
About Dr. Raed Suleiman, MD
Dr. Raed Suleiman, MD is a Sleep Medicine healthcare provider based in Gastonia, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/05/2018. The National Provider Identifier (NPI) number assigned to this provider is 1730657115.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Raed Suleiman, MD has received a total of $168,797 in payments from pharmaceutical and medical device companies, with $26,735 received in 2024. These payments were reported across 376 transactions from 30 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($153,025).
As a Medicare-enrolled provider, Suleiman has provided services to 2,367 Medicare beneficiaries, totaling 3,616 services with total Medicare billing of $243,859. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Sleep Medicine
- Other Specialties Pulmonary Disease
- Location Gastonia, NC
- Active Since 11/05/2018
- Last Updated 10/16/2022
- Taxonomy Code 207RS0012X
- Entity Type Individual
- NPI Number 1730657115
Products in Payments
- BREZTRI (Drug) $159,235
- BREZTRI AEROSPHERE (Drug) $4,985
- TRELEGY ELLIPTA (Drug) $442.23
- AREXVY (Drug) $353.51
- Arikayce (Drug) $348.84
- SMARTVEST (Device) $247.37
- OFEV (Drug) $246.27
- AIRSUPRA (Drug) $224.77
- Prolastin-C Liquid (Biological) $196.34
- DUPIXENT (Biological) $155.06
- NUCALA (Biological) $144.49
- Xolair (Biological) $128.57
- Repatha (Biological) $125.00
- UPTRAVI (Drug) $116.60
- INSPIRE (Device) $112.38
- Yupelri (Drug) $104.59
- STIOLTO RESPIMAT (Drug) $103.20
- OPSUMIT (Drug) $99.57
- FASENRA (Biological) $97.68
- CHARTIS CATHETER (Device) $85.15
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.